Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Nov 12, 2015 3:53pm
257 Views
Post# 24286349

RE:RE:RE: been here since 09' ;)

RE:RE:RE: been here since 09' ;)


Couldnt agree more.  This issue has plagued these guys for over a decade,  its driven me to drink. Wait... I already drank... OK.. its driven me to drink even more !

They have chronically overpromissed and under delivered,  largely because they were almost entirely dependent on OTHER companies execution.

While I know they have "heard" us all on this issue,  I feel the company for a very long time has had an honest addiction to optimism around revenue....  They HAD to in order to keep alive...  and to keep the wolves from the door anticipating the next financing .  But here's the kicker...  " this time is different "... and here is why.

To be clear,  I am not saying that I think they are going to announce a revenue run rate that meets or exceeds expectations.  Although candidly I do believe they will deliver at least $20mm in H2 /15....  but it almost doesnt matter.  This time is different because the market and analysts for the first time are truly starting to appreciate the value that the company is in the process of developing with its proprietary technology,  and how far their various small molecule drugs are in the developmental stages.   As more and more positive results emerge from the various initiatives,  this will become an ever larger story.

In that respect,  more than ever,  the quarterly revenue matters less and less.  In fact,  I wish they would just come out and forecast $25mm in annual rev for the next two years...  and lets focus on the far far bigger prizes.   They can absolutely raise $50-$100mm in a heartbeat right now.... its a non factor like never before in the company's history.

The ultimate irony is this,  the company is transitioning from one that was focussed on recurring revenue ramp derived from Resin sales,  to a company with transformational unique and valuable drugs that are likely going to be worth BILLIONS ( if they arent already )    And the production of those drugs,  if it makes it that far without being bought out,  will require a WHACK of resin... so everbody wins.

so I say,  chill out,  stop with the conspiracy theories of market manipulation this and that.   Get long, stay long.. and 1,3,6,12-18 months from now we will all be much better off.

Bullboard Posts